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Abstract
Background: Specific phobia is the most prevalent anxiety disorder in the community and is associated with
substantial impairment. Comorbidity with physical diseases is assumed and has important implications for etiology,
treatment, or prevention of the comorbid conditions. However, due to methodological issues data are limited and
subtypes of specific phobia have not been investigated yet. We examined the association of specific phobia and its
subtypes with physical diseases in a representative community sample with physician-diagnosed physical diseases
and diagnostic criteria of specific phobia.
Methods: Data of the German Mental Health Survey from 4181 subjects aged 18–65 years were used. Specific
phobia was diagnosed using M-CIDI/DIA-X interview; physical diseases were assessed through a self-report
questionnaire and a medical interview. Logistic regression analyses adjusted for sex were calculated.
Results: Specific phobia was associated with cardiac diseases, gastrointestinal diseases, respiratory diseases, arthritic
conditions, migraine, and thyroid diseases (odds ratios between 1.49 and 2.53). Among the subtypes, different
patterns of associations with physical diseases were established. The findings were partially replicated in the Swiss
PsyCoLaus Study.
Conclusions: Our analyses show that subjects with specific phobia have an increased probability for specific physical
diseases. From these analyses etiological mechanisms of specific phobia and physical disease can be deduced. As
subtypes differed in their patterns of associations with physical diseases, different etiological mechanisms may play a
role. The findings are highly relevant for public health in terms of prevention and therapy of the comorbid conditions.
Keywords: Specific phobia, Comorbidity, Physical diseases, Representative survey
Background
Specific phobia is the most prevalent anxiety disorder in
the community [1, 2]. It is associated with significant
impairment and distress [3] and with a loss of work days
[4]. Further, specific phobia is a predictor for increased
suicidal tendency [5] and it is thought to be a risk factor
for the later development of other mental disorders such
as major depression [6, 7] or anxiety disorders [8]. Add-
itionally, specific phobia is highly comorbid with other
mental disorders, especially with anxiety disorders and
mood disorders [9, 10].
Research has suggested that besides being comorbid
with other mental disorders, specific phobia may be
highly comorbid with physical diseases, too. Having any
anxiety disorder during the last year has been associated
with neurological, vascular, respiratory, gastrointestinal,
metabolic, bone, and infectious diseases [11–14]. Fur-
ther, a longitudinal analysis showed that self-reported
gastrointestinal disease predicted the onset of specific
phobia in older adults during the next three years [15].
Subjects with coronary heart disease reported elevated
levels of phobic anxiety [16] and phobic anxiety is asso-
ciated with cardiac mortality [17]. Among men with high
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levels of phobic anxiety, an increased prevalence rate of
Parkinson’s disease was found compared to men with
low levels of phobic anxiety [18]. Further, a review re-
vealed that subjects with chronic obstructive pulmonary
disease reported a prevalence of 10–17 % of specific
phobia [19]. Community studies in addition established
an association between specific phobia and migraine
[20], respiratory diseases [11], ulcer [21], vascular dis-
eases [22] and heart diseases [23].
Most research has suggested a link between specific
phobia and physical diseases. However, there are meth-
odological issues that limit the generalizability of the
findings. First, not all studies used Diagnostic and
Statistical Manual of Mental Disorders (DSM) [24] or
International Classification of Diseases (ICD) [25] diag-
nostic criteria of specific phobia. Second, the physical
diseases were mainly assessed by self-report rather than
diagnosed by a physician. Third, most studies focused
on one specific physical disease and therefore provide
limited information on the association with different
physical diseases.
Knowledge of the comorbidity of specific phobia and
physical diseases could influence research on the etiology
of both physical diseases and specific phobia through the
detection of possible etiological mechanisms. It is also
highly relevant for public health because some studies
have suggested that anxiety can complicate the treatment
of chronic medical diseases and may therefore be associ-
ated with worse treatment outcomes [26, 27].
DSM-IV differentiates among five specific phobia sub-
types (animal type, natural type, blood-injection-injury
type, situational type and other type), which primarily
differ with respect to content of subjective fear [28].
Variation with respect to age of onset among the sub-
types has also been observed [29]. Further, some studies
established differences among the comorbidity patterns
with other mental disorders [28, 30, 31]: Youths with
specific phobias of the natural type reported more de-
pressive symptoms and showed higher prevalence rates
of other anxiety disorders than youths with animal pho-
bias [32]; situational phobia was associated with more
panic attacks than other specific phobia subtypes [31];
and individuals with blood-injection phobia had a higher
prevalence of marijuana abuse, depression, panic dis-
order, obsessive-compulsive disorder, or social phobia
compared to individuals without blood-injection phobia
[31, 33, 34]. Additionally, subjects with specific phobia
of the natural type reported more somatic symptoms
than subjects with animal phobia [32].
As for the different associations with mental disorders,
subtypes of specific phobia may also show different co-
morbidity patterns with physical diseases. Psychobiological
aspects might help to explain why these differences may
be expected: There is evidence suggesting that different
physiological processes in some biological systems may be
involved in the different fear reaction of specific phobia
subtypes [29]. Subjects with animal phobia show triggered
elevations in heart rate, blood pressure, norepinephrine,
and epinephrine when they are exposed to the phobic
stimulus. Subjects with blood-injection phobia on the
other hand show an initial rise in heart rate and blood
pressure followed by vasovagal fainting characterized by
bradycardia and hypotension [31, 33]. Further, some evi-
dence suggests partially distinct neurobiological substrates
of blood-injection and animal phobia [35, 36]. A study in-
vestigating the neural response during the presentation of
phobia-specific stimuli established that subjects with ani-
mal phobia showed activation in dorsal anterior cingulate
and anterior insula, in comparison to subjects with Blood
Injection Phobia showing activation in the thalamus and
visual/attention areas [35].
Based on these empirical findings, we suggest that specific
phobia subtypes are associated with different physical dis-
eases that may be linked to distinct physiological processes.
Analyses addressing similarities and differences among spe-
cific phobia subtypes are important to elucidate potential
etiological pathways. However, to the best of our knowledge
no study has evaluated the association between specific
phobia subtypes and physical diseases in the community.
Hypotheses
The aim of our study therefore was to analyze the associ-
ation of DSM-IV specific phobia and its subtypes and a
broad range of physical diseases in the German Health
Interview and Examination Survey, Mental Health
Supplement (GHS-MHS). We addressed the methodo-
logical limitations reported above by using a wide range of
physician-diagnosed physical diseases and specific phobia
assessed by a well-validated structured interview. Further,
we aim to replicate the findings in a separate data set, the
baseline investigation of the PsyCoLaus Study.
Based on the established associations between specific
phobia and physical diseases in community samples as
presented above, we specifically hypothesized for our
community sample that
(1)Having any specific phobia is associated with migraine
(2)Having any specific phobia is associated with
respiratory diseases
(3)Having any specific phobia is associated with
gastrointestinal diseases
(4)Having any specific phobia is associated with cardiac
diseases
(5)Having any specific phobia is associated with vascular
diseases
As there is not enough empirical knowledge to formulate
specific hypotheses concerning the associations between
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subtypes of specific phobia and physical diseases, we fur-
ther investigated these associations in an explorative
manner.
Methods
Design and sample of the GHS-MHS
The GHS-MHS, conducted in 1997, was the first nation-
wide cross-sectional study for medical and social assess-
ments in Germany. The GHS-MHS was commissioned by
the German Ministry of Science, Research and Education
and approved by the relevant institutional review board of
the Robert Koch Institute (Berlin, Germany). The aim of
the core study was the assessment of sociodemographic
characteristics, physical diseases, impairments, and
health-care utilization in a representative community sam-
ple of 7,124 subjects ages 18–79 years (overall response
rate 61.5 %). The sample was stratified and randomized
from 113 communities throughout Germany with 130
sampling units (step 1: selection of communities, step 2:
selection of sampling units, step 3: selection of inhabi-
tants) [2, 37]. The data were weighted and confidence in-
tervals were calculated by the Huber–White sandwich
method to account for the weighting scheme as well as
the stratified sampling design [37].
Mental disorders were assessed in a two-stage design:
The first stage entailed the administration of a 12-item
screening questionnaire for mental disorders at the end of
the medical examination of the core survey (the Composite
International Diagnostic Screener) [38]. The second stage
involved the administration of a structured psychopatho-
logical interview, the Munich Composite International
Diagnostic Interview (DIA-X/M-CIDI) to all core survey
respondents who had been screened positive for a mental
disorder and to a random sample of 50 % who screened
negative [38]. This subsample of the GHS is the sample of
the Mental Health Supplement and included 4181 subjects
aged 18–65 years. The M-CIDI interview was completed
by 87.6 % of the subjects (conditional response rate). All
subjects gave their written informed consent. Further de-
scriptions of aims, design, and methods as well as sociode-
mographic characteristics of the whole GHS-MHS sample
can be found elsewhere [37].
Specific phobia in the GHS-MHS
The fully structured DIA-X/M-CIDI interview was used
for the diagnostic assessments in the GHS-MHS [39]
covering both DSM-IV and ICD-10 criteria. Through the
structured interview symptoms, syndromes, onset, dur-
ation and severity were assessed. Trained psychologists
and physicians conducted the interview [37]. The DIA-
X/M-CIDI diagnostic algorithms were used to obtain the
diagnostic findings reported in this paper [40]. There
was substantial test–retest reliability (kappa values be-
tween 0.56 and 0.81) [41]; the sensitivity of the DIA-X/
M-CIDI diagnoses ranges from 87.5 % to 100 %, their
specificity from 71.2 % to 100 % [42]. The validity of the
full diagnoses ranges from moderate to excellent when
compared to diagnoses made by independent treating
physicians in a sample of randomly chosen patients [42].
We used the 12-month DSM-IV diagnosis of specific
phobia. Additionally, the 12-month diagnoses of the fol-
lowing subtypes of specific phobia were used: the animal
subtype (referring to fear related to insects, snakes, birds,
or other animals), the natural subtype (referring to fear re-
lated to height, storm, water), the blood-injection subtype
(referring to fear related to seeing blood, injection, going
to the dentist or hospital), the situational subtype (refer-
ring to flying in a plane, being in a small closed room, in a
cellar, tunnel, or elevator), and the other subtype (referring
to any other specific fear not matching any other subtype).
Physical diseases in the GHS-MHS
Physical diseases were assessed by a self-report question-
naire and a standardized computer-assisted medical inter-
view by a general practice physician. Using the information
on physical diseases in the self-report questionnaire, the
physician collected data on age of onset, lifetime preva-
lence, 12-month prevalence, and point prevalence (4 weeks)
of 44 physical diseases [37]. Blood pressure and anthropo-
metric measurements were conducted and blood and urine
samples were collected. Diagnoses were then supple-
mented and revised based on these laboratory analyses
[37]. The present analyses are based on the physicians’
diagnoses during the medical interview.
Replication study
Design and sample of the PsyCoLaus Study
As a replication study, we used the baseline investigation
of the CoLaus/PsyCoLaus cohort study [43, 44]. CoLaus/
PsyCoLaus conducted in Lausanne, Switzerland, was de-
signed to study mental disorders and cardiovascular risk
factors in the general population. The subjects aged 35–75
years were randomly selected through the population
register of the city of Lausanne. All participants of the
somatic investigation (CoLaus) aged between 35 and
66 years were asked to also undergo a comprehensive psy-
chiatric evaluation (PsyCoLaus), resulting in a subsample
of 3720 subjects (response rate: 67 %) [44]. The psychiatric
assessment took place between 2004 and 2008.
Specific phobia in the PsyCoLaus Study
The psychiatric evaluation in PsyCoLaus was based on the
French version of the semi-structured Diagnostic Interview
for Genetic Studies (DIGS; [45, 46]), which elicits DSM-IV
axis I criteria and suicidal behavior and extensive informa-
tion on the course and chronology of comorbid conditions.
As the phobia section of the original DIGS interview was
brief [46] it was replaced by the chapter from the
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semi-structured Schedule for Affective Disorders and
Schizophrenia – Lifetime Version (SADS-LA) [47, 48].
The semi-structured interview revealed excellent inter-
rater and fair to good test-retest reliability for major mood
and psychotic disorders [49, 50]. Regarding anxiety disor-
ders, applying the French translation of the SADS-LA,
Leboyer et al. [46] found satisfactory test-retest reli-
ability (mean interval 3.2 months) for panic disorder/
agoraphobia (Yule’s Y = 0.43), Generalized Anxiety
Disorder (GAD) (Yule’s Y = 0.61) and phobic disorders
(Yule’s Y = 0.66). The Yule coefficient for the overall
category of anxiety disorders was 0.49. Our own reliability
study [50], based on a sample of 136 patients who also
completed the combined DIGS – SADS-LA section for
specific anxiety disorders, revealed perfect inter-rater
agreement for all specific anxiety disorders except for
agoraphobia (Yule’s Y = 0.96). The Yule’s Y coefficients for
the 6-week test-retest reliability were 0.58 for panic dis-
order, 0.55 for agoraphobia, 0.44 for social phobia, 0.77 for
specific phobia and 0.64 for OCD. Regarding GAD, no
test-retest agreement was obtained.
During the interview, the subjects were asked if they
had experienced symptoms of anxiety during certain situa-
tions related to the DSM-IV subtypes of specific phobia
during their lifetime (e.g. “Did you feel anxious when you
were flying in a plane?” or “Did you feel anxious when you
were facing a certain animal?”). Subtypes were then de-
rived from the information collected during the interview.
For our analyses, the following subtypes were created
based on DSM-IV criteria (comparable to those of the
GHS-MHS): animal, natural, situational, blood-injection
and the other subtype. As the ages of onset and offset of
each disorder were assessed, 12 month prevalence of spe-
cific phobia and its subtypes could be established.
Physical diseases in the PsyCoLaus Study
Cardiovascular and metabolic diseases were assessed
during the physical CoLaus evaluation through a med-
ical interview, physical examinations and blood and
urine tests. Moreover, in the medical part of the DIGS
interview during the psychiatric evaluation information
was collected on additional physical lifetime diseases.
During this evaluation age at onset information for phys-
ical diseases were also collected.
For the present analyses, we used data from the
CoLaus and PsyCoLaus Studies. Cardiac diseases and
vascular diseases were diagnosed during the CoLaus
Study by an adjudication committee according to the lat-
est diagnostic criteria, and diagnoses of hypertension
and diabetes were based on measurements of blood
pressure and fasting glucose [43]. For the other groups
of diseases data stemmed from the medical part of the
psychiatric interview. To enable comparison with the
GHS-MHS, the same groups of physical diseases were
built. However, in the groups of cardiac diseases, arth-
ritic conditions and vascular diseases not all or different
physical diseases were assessed among these groups in
both studies (as indicated in Table 1).
Ethics, consent and permissions
All subjects of the GHS-MHS and the PsyCoLaus
Study gave their written informed consent. The GHS-
MHS was commissioned by the German Ministry of
Science, Research and Education and approved by the
relevant institutional review board of the Robert Koch
Table 1 Frequency of specific phobia and its subtypes and
physical diseases in the GHS-MHS (12 months) and the
PsyCoLaus Study (12 months for specific phobia and lifetime
for physical diseases)
Phobia/disease GHS-MHS PsyCoLaus
No. % No. %
Any specific phobiaa 388 7.6 518 13.9
Subtypesb
Animal subtype 68 1.5 112 3.0
Natural subtype 75 1.4 37 1.0
Blood-injection subtype 64 1.5 18 0.5
Situational subtype 89 1.8 48 1.3
Other subtype 3 0.08 10 0.3
Hypertension 581 13.1 1110 29.8
Cardiac diseases (heart circulation
disturbances, narrowing of the
coronary vessels, angina pectoris,
cardiac infarct, heart weakness,
heart insufficiency)c
100 2.2 199 5.3
Respiratory diseases
(asthma, chronic bronchitis)
284 7.0 572 15.3
Gastrointestinal diseases (ulcer, gastritis) 268 6.3 252 6.7
Diabetes (with or without insulin treatment) 115 2.7 194 5.2
Arthritic conditions (wear and tear type,
inflammatory diseases of the joints)d
1107 25.9 773 20.8
Allergies (hay fever, allergic eczema,
allergic hives, neurodermatitis, food
allergy, allergic conjunctivitis)
747 18.1 1018 27.3
Migraine headaches 491 10.3 562 15.2
Neurological diseases (epilepsy,
Parkinson’s disease, multiple sclerosis)
27 0.5 94 2.5
Thyroid diseases 445 10.0 164 4.4
Vascular diseases (stroke, brain circulation
disturbance, leg circulation disturbance, artery
occlusion, varicose veins, vein thrombosis)e
536 12.4 303 8.2
Note. No: Unweighted number of subjects; %: Percentage (in the GHS-MHS:
weighted percentage), GHS-MHS German Health Survey, Mental Health Supplement
aIncluding animal, natural, blood-injection, situational, or any other subtype.
bsubjects did not fulfill the criteria of any other subtype. cIn the PsyCoLaus Study:
coronary artery disease, angina, myocardial infarct, percutaneous coronary
intervention, coronary artery bypass graft, pacing, heart failure, valvular
heart disease, cardiomyopathy. dIn the PsyCoLaus Study: rheumatoid arthritis,
osteoarthritis, arthritis. eIn the PsyCoLaus Study: arrhythmia, stroke, peripheral
artery disease
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Institute (Berlin, Germany). The Ethics Committee of the
University of Lausanne approved both the physical
(CoLaus) and psychiatric (PsyCoLaus Study) evaluation.
All subjects gave their written informed consent [44].
Statistical analyses
Logistic regression analyses were used to evaluate the as-
sociation of specific phobia and physical diseases in both
the GHS-MHS and the PsyCoLaus Study (specific pho-
bia as predictor, physical diseases as outcome). As spe-
cific phobia and physical diseases were both associated
with sex, the associations between the two were con-
trolled for sex. To further investigate the impact of sex
on the results, we checked the interactions of sex and
specific phobia on the association with physical diseases.
Additionally, using the age of onset data available for
both specific phobia and physical diseases, we evaluated
the temporal order of onset of comorbid cases. We con-
sidered a p value <0.05 as statistically significant. The
analyses in the GHS-MHS study were carried out using
STATA 11.0 [51]. The analyses in the PsyCoLaus Study
were carried out using SPSS version 20 [52].
Results
The 12-month prevalence of specific phobia and physical
diseases in the GHS-MHS
In the GHS-MHS, the 12-month prevalence of specific
phobia was 7.6 %, as shown in Table 1. The most preva-
lent subtype of specific phobia was the situational sub-
type (1.8 %), and the other subtype was the least
prevalent (0.08 %). The most prevalent physical diseases
were arthritic conditions with a 12-month prevalence of
25.9 %, followed by allergies (18.1 %). The least prevalent
physical diseases were neurological diseases (0.5 %).
Association between specific phobia and physical
diseases in the GHS-MHS (hypotheses 1–5)
As shown in Table 2, having any specific phobia was asso-
ciated with cardiac diseases, gastrointestinal diseases, re-
spiratory diseases, arthritic conditions, migraine, and
thyroid diseases (odds ratios [ORs] ranging between 1.49,
95 % CI [1.15–1.92], for arthritic conditions and 2.53, CI
[1.73–3.69], for gastrointestinal diseases). Additionally,
having any specific phobia was associated with any phys-
ical disease (OR = 1.87, [1.30–2.68]). Therefore Hypoth-
eses 1–4 could be confirmed, whereas Hypothesis 5 had
to be rejected as no association between any specific pho-
bia and vascular diseases could be proved.
Further, no significant interactions between sex and
specific phobia on the association with physical diseases
were established. Therefore associations do not differ
among men and women.
Among subtypes, the situational subtype was associ-
ated with the most (4 of 10) physical diseases, whereas
only one association was found between the natural sub-
type (migraine, OR = 2.40, 95 % CI [1.29–4.45]) and the
blood-injection subtype (respiratory diseases, OR = 2.14,
95 % CI [1.05–4.36]) and physical diseases. Gastrointes-
tinal diseases, respiratory diseases, migraine, and thyroid
diseases were all associated with two subtypes.
Age of onset
As shown in Table 3, in the GHS-MHS across all phys-
ical diseases most comorbid cases had the onset of spe-
cific phobia before the onset of physical diseases.
Replication analysis
In the CoLaus/PsyCoLaus Study, any specific phobia
was associated with gastrointestinal, respiratory, arthritic
conditions, allergic diseases and migraine (ORs ranging
between 1.30, 95 % CI [1.04–1.63], for arthritic condi-
tions and 1.68, 95 % CI [1.33–2.13], for migraine). Fur-
ther, having any specific phobia was associated with
having any physical disease (OR = 1.34, 95 % CI [1.07–
1.68]). In this sample, Hypotheses 1–3 could be con-
firmed. As no associations between specific phobia and
cardiac and vascular diseases could be established, Hy-
potheses 4 and 5 were rejected.
Among subtypes, the animal and natural subtype were
associated with respiratory diseases (animal: OR = 1.62,
95 % CI [1.02–2.55]; natural: OR = 2.36, 95 % CI [1.16–
4.82]) and migraine (animal: OR = 1.71, 95 % CI [1.09–
2.69]; natural: OR = 2.38, 95 % CI [1.16–4.85]). Addition-
ally, the natural subtype was associated with having any
physical disease (OR = 3.03, 95 % CI [1.06–8.57]; No other
associations were found between subtypes of specific pho-
bia and physical diseases in the PsyCoLaus Study. Results
of the PsyCoLaus data are available on request.
Further, similar to the GHS-MHS data across all phys-
ical diseases most comorbid cases had the onset of spe-
cific phobia before the onset of physical diseases (results
available on request).
Discussion
The aim of our study was to determine the association
between specific phobia and its subtypes and physical
diseases in a general population sample to extend infor-
mation from earlier studies by using improved methods
(physician-diagnosed physical diseases, standardized diag-
nostics of specific phobia, a wide range of physical diseases
assessed within one sample). Our study suggests an asso-
ciation of specific phobia and several physical diseases in
the community. In line with earlier studies, we found an
association between specific phobia and respiratory dis-
eases [11, 53], heart diseases [16, 17], vascular diseases
[22] and cardiac diseases [23]. An association with gastro-
intestinal diseases has also been found, but in comparison
to our study the association did not remain significant
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Table 2 Odds ratios and confidence intervals of physical diseases (12 months) for specific phobia and its subtypes (12 months) compared to a reference group that had no
specific phobia during the past 12 months in the German Health Interview and Examination Survey – Mental Health Supplement (N = 4,181)
Phobia Physical disease
Hypertension
(n = 581)
Cardiac
diseases
(n = 100)
Gastro-intestinal
diseases
(n = 268)
Respiratory
diseases
(n = 284)
Diabetes
(n = 115)
Arthritic
conditions
(n = 1107)
Allergies
(n = 747)
Migraine
(n = 491)
Neurological
diseases
(n = 27)
Thyroid
diseases
(n = 445)
Vascular
diseases
(n = 536)
Any physical
disease
(n= 2602)
Any specific phobia
(n = 388)
1.22
(0.88–1.67)
(n = 69)
1.94
(1.05–3.57)*
(n = 16)
2.53
(1.73–3.69)*
(n = 47)
2.20
(1.52–3.16)*
(n = 49)
1.26
(0.63–2.51)
(n = 12)
1.49
(1.15–1.92)*
(n = 131)
1.29
(0.94–1.76)
(n = 80)
1.99
(1.47–2.69)*
(n = 78)
0.68
(0.09–4.95)
(n = 1)
1.72
(1.24–2.37)*
(n = 69)
1.17
(0.83–1.65)
(n = 62)
1.87
(1.30–2.68)*
(n = 289)
Animal subtypeb
(n = 68)
0.88
(0.39–1.97)
(n = 8)
2.76
(0.82–9.17)
(n = 3)
3.53
(1.73–7.19)*
(n = 14)
2.52
(1.10–5.76)*
(n = 8)
1.92
(0.45–8.15)
(n = 2)
0.93
(0.48–1.78)
(n = 15)
2.02
(1.008–4.05)*
(n = 18)
1.54
(0.79–2.99)
(n = 13)
4.07
(0.52–31.37)
(n = 1)
1.44
(0.73–2.86)
(n = 13)
1.04
(0.49–2.20)
(n = 10)
1.24
(0.53-2.87)
(n = 48)
Natural subtypeb
(n = 75)
1.45
(0.75–2.80)
(n = 15)
2.28
(0.76–6.87)
(n = 4)
2.53
(0.99–6.41)
(n = 6)
1.66
(0.62–4.38)
(n = 6)
0.86
(0.19-3.81)
(n = 2)
1.55
(0.90–2.65)
(n = 26)
1.28
(0.61–2.65)
(n = 13)
2.40
(1.29–4.45)*
(n = 17)
−a 1.41
(0.70–2.80)
(n = 13)
1.74
(0.89–3.40)
(n = 16)
2.02
(0.99–4.09)
(n = 58)
Blood-injection
subtypeb (n = 63)
0.89
(0.38–2.06)
(n = 8)
2.05
(0.47–8.80)
(n = 2)
2.20
(0.89–5.39)
(n = 6)
2.14
(1.05-4.36)*
(n = 10)
1.03
(0.14–7.49)
(n = 1)
1.25
(0.68–2.25)
(n = 19)
0.84
(0.40–1.73)
(n = 9)
1.60
(0.71–3.55)
(n = 8)
−a 1.56
(0.64–3.73)
(n = 7)
0.75
(0.30–1.85)
(n = 6)
0.99
(0.50–1.95)
(n = 35)
Situational subtypeb
(n = 88)
1.49
(0.86–2.56)
(n = 22)
1.81
(0.64–5.14)
(n = 5)
2.35
(1.14–4.85)*
(n = 10)
1.63
(0.77–3.44)
(n = 9)
1.17
(0.40–3.44)
(n = 4)
1.82
(1.12–2.93)*
(n = 34)
0.84
(0.46-1.52)
(n = 17)
2.08
(1.16–3.70)*
(n = 18)
−a 2.55
(1.42–4.57)*
(n = 21)
0.71
(0.36–1.37)
(n = 13)
1.70
(0.76-3.80)
(n = 69)
Otherb (n = 3) −a −a −a −a −a −a −a −a −a 29.91
(2.36-378.42)*
(n = 2)
−a 1.55
(0.12–19.62)
(n= 2)
Note.CI confidence interval, DSM-IV Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, NOS not other specified, OR Odds Ratio, n unweighted number of subjects, % weighted percentage, *p < 0.05,
aempty cell size, bSubjects did not fulfill the criteria of any other subtype, adjusted for sex
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after adjusting for sex [15]. Additionally, we established an
association between specific phobia and arthritic condi-
tions, migraine, and thyroid diseases. We could replicate
the associations between any specific phobia and gastro-
intestinal diseases, respiratory diseases, arthritic condi-
tions and migraine in the PsyCoLaus Study. Associations
with these physical diseases have already been docu-
mented within the GHS-MHS for the group of anxiety
disorders [11]. Further, our analyses did not provide evi-
dence for associations between specific phobia and vascu-
lar diseases in both data sets. This is not in line with an
earlier community based study that established associa-
tions between specific phobia and cardiovascular diseases
[22]. While we distinguished between cardiac and vascular
diseases in two groups as shown in Table 1, the study by
Goodwin et al. (2009) only used one group of cardiovascu-
lar diseases. Therefore it may be possible that the differ-
ences in the established associations may be due to
methodological differences.
In addition, even though previous research showed
that there are gender differences among specific phobia
subtypes [31] and among certain physical diseases such
as cardiac diseases [54], we did not establish differences
in the associations between specific phobia subtypes and
physical diseases among men and women.
Different models can be considered for the explanation
of the comorbidity of specific phobia and physical dis-
eases (specific phobia may be an antecedent or a conse-
quent factor of a specific physical disease; there may be
common biological or social factors that increase the
risk of having both specific phobia and physical diseases;
or a third variable may contribute to the comorbidity
through an indirect mechanism). Our age at onset ana-
lyses show that in most cases specific phobia preceded
the physical diseases. Therefore our data suggest that
the most probable model at the moment is that a pre-
ceding specific phobia increases the risk of subsequent
physical disease. Further it may be that a third variable
contributes to the comorbidity through an indirect
mechanism. The other sequence – a preceding physical
disease and a subsequent specific phobia – is the least
probable model based on our data. Such analyses can
contribute to the deduction of possible etiological path-
ways of both specific phobia and physical diseases.
It has been suggested that certain pathophysiological
mechanisms related to affective and anxiety disorders, such
as sympathoadrenal hyperactivity, reduced heart-rate vari-
ability, heightened platelet activity, and endothelial dysfunc-
tion, may be of interest in the etiology of heart diseases,
too [23]. Additionally, ventricular arrhythmia and hyper-
ventilation causing coronary spasm have been named as
possible mechanisms by which phobic anxiety and there-
fore specific phobia cause coronary heart disease [16, 55].
As a plausible explanation for the comorbidity of
gastrointestinal and anxiety disorders it has been sug-
gested that anxiety could lead to an irritation of the
gastrointestinal system, leading to a gastrointestinal dis-
ease [56]. It has also been shown that the neurotransmit-
ter serotonin, which is implicated in anxiety disorders in
general and specifically in specific phobia [57], is also
known to affect the gastrointestinal system [58].
It has been suggested that anxiety may lead to hyperven-
tilation which is associated with asthma, too [59]. Further,
it has been discussed that shared etiological factors (either
environmental or genetic) of some anxiety disorders and
asthma may account for the comorbidity [60].
Arthritic conditions have mainly been associated with
depression, but anxiety disorders seem to be rather com-
mon in subjects with arthritis, too [61]. For the evalu-
ation of possible shared etiological factors the following
may be considered: certain cytokines and immunglobu-
lins that seem to play a role in arthritic conditions may
be associated with mental disorders, too [62].
Several studies have discussed the association of mi-
graine and psychopathology [20, 63, 64]. Psychosocial fac-
tors related to stress and therefore specific phobia can act
as a trigger for migraine [20]. Additionally, a diminished
serotonin level, which is also associated with anxiety disor-
ders, has been detected in subjects with migraine [63].
Further, psychosocial factors such as avoidance of certain
situations during anxiety may trigger migraine [63].
An increased rate of subjects with specific phobia has
been documented in thyroid disease compared to sub-
jects in the general population [65, 66]. Common neuro-
chemical abnormalities have been identified as a possible
link between anxiety and thyroid disease [65].
Beside the association between specific phobia and phys-
ical diseases, different patterns of associations between the
Table 3 Temporal sequence of age of onset of specific phobia
and physical diseases among those with comorbidity in the
GHS-MHS
Physical disease Comorbid cases where specific phobia
preceded physical condition (%)
Hypertension 82.1
Cardiac Diseases 78.1
Gastrointestinal Diseases 82.0
Respiratory Diseases 80.3
Diabetes 93.0
Arthritic Conditions 77.4
Allergies 73.7
Migraine 72.2
Neurological 0a
Thyroid Diseases 79.2
Vascular Diseases 72.3
aN = 1
Witthauer et al. BMC Psychiatry  (2016) 16:155 Page 7 of 10
subtypes of specific phobia and physical diseases have been
detected. Most associations were found between the situ-
ational subtype and physical diseases. This is in line with a
finding from an earlier study that situational phobia has
higher rates of comorbid psychopathology than animal
and natural phobias [67]. Another study found more som-
atic symptoms in subjects with natural phobia compared
to subjects with animal phobia [32], which might suggest a
somatic vulnerability of the natural subtype. In our study,
however, the natural subtype was only associated with one
physical disease.
The different patterns of associations between the sub-
types and physical diseases may point toward different
etiological mechanisms that need to be addressed in fu-
ture studies. As blood-injection phobia is—alone of the
subtypes—associated with vasovagal fainting [31], it could
be, for instance, that people with this phobia profit from
their rather low blood pressure, leading to a reduction of
their risk for certain physical ailments, such as cardiovas-
cular diseases or hypertension. Unfortunately, power is-
sues precluded evaluating the impact of blood pressure on
the association of specific phobia and cardiovascular dis-
eases. This should therefore be evaluated in future studies.
The current study has a number of limitations. First,
the subjects assessed were between 18 and 65 years of
age. Therefore the results cannot be generalized to youn-
ger or older subjects. Second, some diagnoses may rely
more on self-report data (e.g. arthritis) than other (e.g.
diabetes) [11]. This could lead to over-reporting of cer-
tain symptoms in subjects with specific phobia. Third,
no conclusions concerning the causal nature of the asso-
ciations between specific phobia and physical diseases
can be drawn. Longitudinal evaluation of the associa-
tions found is needed. Fourth, although the sample size
is 4181 subjects, the combination of physical diseases
and specific phobia led to relatively small cell sizes, espe-
cially in the subtype analyses in the GHS-MHS. Fifth,
the comparability of the GHS-MHS and PsyCoLaus
study was limited with respect to methodology used and
data collected, as different timeframes (12 months vs.
lifetime diagnosis of physical diseases) and different age
ranges of subjects (18–65 vs. 35–66 years) were used.
Further, not all physical diseases were assessed in both
studies. Accordingly, it was not surprising that the re-
sults from the GHS-MHS study could be partially repli-
cated. Several associations were only observed in the
GHS-MHS study, which could be attributable to the
younger age of the sample. Indeed, in the older CoLaus/
PsyCoLaus sample the prevalence of almost all physical
diseases was considerably higher than in the GHS-MHS
study and it is therefore possible that an increased num-
ber of age related factors predisposing to these diseases
could have blurred their association with specific phobia
in CoLaus/PsyCoLaus.
Despite these limitations, our study shows that specific
phobia is highly comorbid with different physical dis-
eases. Moreover, the different subtypes show different
patterns of comorbidity with physical diseases in a com-
munity sample.
The comorbidity of specific phobia and physical diseases
has been rarely evaluated until now. However, the findings
in our community sample support the importance of fur-
ther research within this field, as the comorbidity may influ-
ence the burden of subjects affected [13, 14]. Additionally,
this knowledge may be highly relevant for health care policy
as studies showed that anxiety disorders may be associated
with noncompliance [27] or worse treatment outcome of
the physical disease [26]. This means that therapy of anxiety
symptoms may not only lead to a reduction of anxiety but
also to a better therapy outcome of the physical disease.
Last but not least given that our cross-sectional associ-
ations are proved in a longitudinal model and we pre-
sume a causal relationship between specific phobia and
the different physical diseases this may also have import-
ant implications for prevention. Therapy of specific pho-
bia may then reduce the probability of specific physical
diseases.
Conclusions
Our community study shows that specific phobia is as-
sociated with an increased probability of specific physical
diseases and that the subtypes may differ in their comor-
bidity patterns with physical diseases. These findings are
highly relevant for etiological considerations and crucial
for public health aspects, such as treatment, and preven-
tion of the comorbid conditions.
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